Brain Atrophy Assessment in Multiple Sclerosis: Importance and Limitations

Neuroimaging Clinics of North America

Volumn 18, Issue 4, 2008, Pages 675-686

  Giorgio, Antonio ^a,b   Battaglini, Marco ^a   Smith, Stephen M ^b   De Stefano, Nicola ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Brain atrophy; Multiple sclerosis; Tissue damage

Indexed keywords

BRAIN ATROPHY; BRAIN SIZE; BRAIN TISSUE; CEREBROSPINAL FLUID; COGNITION; COMPUTER PROGRAM; GRAY MATTER; HISTOLOGY; HUMAN; MATHEMATICAL COMPUTING; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; WHITE MATTER;

ATROPHY; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; ORGAN SIZE; PROGNOSIS;

EID: 54949093619     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2008.06.007     Document Type: Review

References (126)

1. Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?. Neurology 68 (2007) S72-S82 [discussion: S91-76]
2. De Stefano N., Battaglini M., and Smith S.M. Measuring brain atrophy in multiple sclerosis. J Neuroimaging 17 Suppl 1 (2007) 10S-15S
3. Simon J.H. Brain atrophy in multiple sclerosis: what we know and would like to know. Mult Scler 12 (2006) 679-687
4. Bermel R.A., and Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5 (2006) 158-170
5. Rudick R.A., Fisher E., Lee J.C., et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53 (1999) 1698-1704
6. Collins D.L., Montagnat J., Zijdenbos A.P., et al. Automated estimation of brain volume in multiple sclerosis with BICCR. Lect Notes Comput Sci 2082 (2001) 141-147
7. Udupa J.K., Wei L., Samarasekera S., et al. Multiple sclerosis lesion quantification using fuzzy-connectedness principles. IEEE Trans Med Imaging 16 (1997) 598-609
8. Alfano B., Brunetti A., Covelli E.M., et al. Unsupervised, automated segmentation of the normal brain using a multispectral relaxometric magnetic resonance approach. Magn Reson Med 37 (1997) 84-93
9. Guttmann C.R., Benson R., Warfield S.K., et al. White matter abnormalities in mobility-impaired older persons. Neurology 54 (2000) 1277-1283
10. Dade L.A., Gao F.Q., Kovacevic N., et al. Semiautomatic brain region extraction: a method of parcellating brain regions from structural magnetic resonance images. Neuroimage 22 (2004) 1492-1502
11. Fischl B., Sereno M.I., and Dale A.M. Cortical surface-based analysis. II. Inflation, flattening, and a surface-based coordinate system. Neuroimage 9 (1999) 195-207
12. Dale A.M., Fischl B., and Sereno M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 9 (1999) 179-194
13. Sailer M., Fischl B., Salat D., et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 126 (2003) 1734-1744
14. Smith S.M., Zhang Y., Jenkinson M., et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17 (2002) 479-489
15. Smith S.M., Jenkinson M., Woolrich M.W., et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23 Suppl 1 (2004) S208-S219
16. Ashburner J., and Friston K.J. Voxel-based morphometry-the methods. Neuroimage 11 (2000) 805-821
17. Good C.D., Johnsrude I.S., Ashburner J., et al. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14 (2001) 21-36
18. Nichols T.E., and Holmes A.P. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 15 (2002) 1-25
19. Battaglini M., Smith S.M., Douad G., et al. Voxel-based analysis of global and neocortical progression of brain atrophy in RRMS. [abstract]. ISMRM (2007)
20. Fox N.C., Jenkins R., Leary S.M., et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 54 (2000) 807-812
21. Smith S.M., De Stefano N., Jenkinson M., et al. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 25 (2001) 466-475
22. Bartsch A.J., Homola G., Biller A., et al. Manifestations of early brain recovery associated with abstinence from alcoholism. Brain 130 (2007) 36-47
23. De Stefano N., Jenkinson M., Guidi L., et al. Voxel-level cross-subject statistical analysis of brain atrophy in early relapsing remitting MS patients. Int Soc Magn Reson Med [book of abstracts] 2 (2003) 2625
24. Smith S.M., Rao A., De Stefano N., et al. Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage 36 (2007) 1200-1206
25. Anderson V.M., Fernando K.T., Davies G.R., et al. Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods. J Neuroimaging 17 (2007) 61-68
26. Anderson V.M., Fox N.C., and Miller D.H. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging 23 (2006) 605-618
27. Coffey C.E., Wilkinson W.E., Parashos I.A., et al. Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging. Neurology 42 (1992) 527-536
28. Pfefferbaum A., Mathalon D.H., Sullivan E.V., et al. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arch Neurol 51 (1994) 874-887
29. Brex P.A., Jenkins R., Fox N.C., et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54 (2000) 1689-1691
30. Dalton C.M., Brex P.A., Jenkins R., et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 73 (2002) 141-147
31. Chard D.T., Griffin C.M., Parker G.J., et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 125 (2002) 327-337
32. Rudick R.A., Fisher E., Lee J.C., et al. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 6 (2000) 365-372
33. Turner B., Lin X., Calmon G., et al. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 9 (2003) 21-27
34. Stevenson V.L., Miller D.H., Leary S.M., et al. One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 68 (2000) 713-718
35. Rovaris M., Judica E., Gallo A., et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain 129 (2006) 2628-2634
36. Sastre-Garriga J., Ingle G.T., Chard D.T., et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain 128 (2005) 1454-1460
37. Leary S.M., Miller D.H., Stevenson V.L., et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 60 (2003) 44-51
38. Ingle G.T., Stevenson V.L., Miller D.H., et al. Two-year follow-up study of primary and transitional progressive multiple sclerosis. Mult Scler 8 (2002) 108-114
39. Filippi M., Rovaris M., Iannucci G., et al. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55 (2000) 1714-1718
40. Kalkers N.F., Ameziane N., Bot J.C., et al. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 59 (2002) 1572-1576
41. Matthews P.M., De Stefano N., Narayanan S., et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 18 (1998) 327-336
42. Filippi M., and Inglese M. Overview of diffusion-weighted magnetic resonance studies in multiple sclerosis. J Neurol Sci 186 Suppl 1 (2001) S37-S43
43. Chard D.T., Griffin C.M., McLean M.A., et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 125 (2002) 2342-2352
44. Calabrese M., De Stefano N., Atzori M., et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 64 (2007) 1416-1422
45. Bjartmar C., and Trapp B.D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14 (2001) 271-278
46. Lucchinetti C.F., Bruck W., and Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 56 (2004) 308
47. Bruck W. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. J Neurol 252 Suppl 5 (2005) v10-v15
48. Wegner C., Esiri M.M., Chance S.A., et al. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 67 (2006) 960-967
49. Peterson J.W., Bo L., Mork S., et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50 (2001) 389-400
50. Dalton C.M., Chard D.T., Davies G.R., et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 127 (2004) 1101-1107
51. De Stefano N., Matthews P.M., Filippi M., et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 60 (2003) 1157-1162
52. Ge Y., Grossman R.I., Udupa J.K., et al. Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter. Radiology 220 (2001) 606-610
53. Quarantelli M., Ciarmiello A., Morra V.B., et al. Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. Neuroimage 18 (2003) 360-366
54. Tiberio M., Chard D.T., Altmann D.R., et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 64 (2005) 1001-1007
55. Chard D.T., Griffin C.M., Rashid W., et al. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 10 (2004) 387-391
56. Valsasina P., Benedetti B., Rovaris M., et al. Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology 65 (2005) 1126-1128
57. Prinster A., Quarantelli M., Orefice G., et al. Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study. Neuroimage 29 (2006) 859-867
58. Carone D.A., Benedict R.H., Dwyer M.G., et al. Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. Neuroimage 29 (2006) 505-514
59. Sepulcre J., Sastre-Garriga J., Cercignani M., et al. Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. Arch Neurol 63 (2006) 1175-1180
60. Calabrese M., Atzori M., Bernardi V., et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 254 (2007) 1212-1220
61. Charil A., Dagher A., Lerch J.P., et al. Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability. Neuroimage 34 (2007) 509-517
62. Jasperse B., Vrenken H., Sanz-Arigita E., et al. Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis. Neuroimage 38 (2007) 529-537
63. Pagani E., Rocca M.A., Gallo A., et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol 26 (2005) 341-346
64. Chen J.T., Narayanan S., Collins D.L., et al. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage 23 (2004) 1168-1175
65. Bermel R.A., Innus M.D., Tjoa C.W., et al. Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study. Neuroreport 14 (2003) 335-339
66. Wylezinska M., Cifelli A., Jezzard P., et al. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology 60 (2003) 1949-1954
67. Audoin B., Davies G.R., Finisku L., et al. Localization of grey matter atrophy in early RRMS: a longitudinal study. J Neurol 253 (2006) 1495-1501
68. Houtchens M.K., Benedict R.H., Killiany R., et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 69 (2007) 1213-1223
69. Cifelli A., Arridge M., Jezzard P., et al. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 52 (2002) 650-653
70. Mesaros S., Rocca M.A., Absinta M., et al. Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology 70 (2008) 1107-1112
71. Tedeschi G., Lavorgna L., Russo P., et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 65 (2005) 280-285
72. Martola J., Stawiarz L., Fredrikson S., et al. Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development. J Neurol Neurosurg Psychiatry 78 (2007) 375-380
73. Luks T.L., Goodkin D.E., Nelson S.J., et al. A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis. Mult Scler 6 (2000) 332-337
74. Dalton C.M., Miszkiel K.A., O'Connor P.W., et al. Ventricular enlargement in MS: one-year change at various stages of disease. Neurology 66 (2006) 693-698
75. McDonald W.I., Miller D.H., and Thompson A.J. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta. Ann Neurol 36 (1994) 14-18
76. McDonald W.I. Rachelle Fishman-Matthew Moore Lecture. The pathological and clinical dynamics of multiple sclerosis. J Neuropathol Exp Neurol 53 (1994) 338-343
77. Trapp B.D., Ransohoff R., and Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12 (1999) 295-302
78. Trapp B.D., Bo L., Mork S., et al. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 98 (1999) 49-56
79. Sanfilipo M.P., Benedict R.H., Sharma J., et al. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage 26 (2005) 1068-1077
80. Losseff N.A., Wang L., Lai H.M., et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 119 Pt 6 (1996) 2009-2019
81. Ge Y., Grossman R.I., Udupa J.K., et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 214 (2000) 665-670
82. Bakshi R., Benedict R.H., Bermel R.A., et al. Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. J Neuroimaging 11 (2001) 129-136
83. Molyneux P.D., Kappos L., Polman C., et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive multiple sclerosis. Brain 123 Pt 11 (2000) 2256-2263
84. Fisher E., Rudick R.A., Simon J.H., et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59 (2002) 1412-1420
85. Pelletier J., Suchet L., Witjas T., et al. A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol 58 (2001) 105-111
86. Feinstein A., Kartsounis L.D., Miller D.H., et al. Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study. J Neurol Neurosurg Psychiatry 55 (1992) 869-876
87. Amato M.P., Ponziani G., Pracucci G., et al. Cognitive impairment in early-onset multiple sclerosis: pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 52 (1995) 168-172
88. Rovaris M., Filippi M., Falautano M., et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology 50 (1998) 1601-1608
89. Filippi M., Tortorella C., Rovaris M., et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry 68 (2000) 157-161
90. Zivadinov R., De Masi R., Nasuelli D., et al. MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis. Neuroradiology 43 (2001) 272-278
91. Amato M.P., Bartolozzi M.L., Zipoli V., et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 63 (2004) 89-93
92. Benedict R.H., and Zivadinov R. Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci 245 (2006) 67-72
93. Sanfilipo M.P., Benedict R.H., Weinstock-Guttman B., et al. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 66 (2006) 685-692
94. Locatelli L., Zivadinov R., Grop A., et al. Frontal parenchymal atrophy measures in multiple sclerosis. Mult Scler 10 (2004) 562-568
95. Tekok-Kilic A., Benedict R.H., Weinstock-Guttman B., et al. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. Neuroimage 36 (2007) 1294-1300
96. Matthews P.M., and Arnold D.L. Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution. Curr Opin Neurol 14 (2001) 279-287
97. Mainero C., De Stefano N., Iannucci G., et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology 56 (2001) 1331-1334
98. Frank J.A., Richert N., Bash C., et al. Interferon-beta-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and NAb+ patients. Neurology 62 (2004) 719-725
99. Hardmeier M., Wagenpfeil S., Freitag P., et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 64 (2005) 236-240
100. Gasperini C., Paolillo A., Giugni E., et al. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. Mult Scler 8 (2002) 119-123
101. Filippi M., Rovaris M., Inglese M., et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 1489-1496
102. Rovaris M., Comi G., Rocca M.A., et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 124 (2001) 1803-1812
103. Miller D.H., Soon D., Fernando K.T., et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68 (2007) 1390-1401
104. Mancardi G.L., Saccardi R., Filippi M., et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57 (2001) 62-68
105. Roccatagliata L., Rocca M., Valsasina P., et al. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult Scler 13 (2007) 1068-1070
106. Trapp B.D., Peterson J., Ransohoff R.M., et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 (1998) 278-285
107. Evangelou N., Konz D., Esiri M.M., et al. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 124 (2001) 1813-1820
108. Arnold D.L. Changes observed in multiple sclerosis using magnetic resonance imaging reflect a focal pathology distributed along axonal pathways. J Neurol 252 Suppl 5 (2005) v25-v29
109. Garbern J.Y., Yool D.A., Moore G.J., et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 125 (2002) 551-561
110. Helms G. T2-based segmentation of periventricular paragraph sign volumes for quantification of proton magnetic paragraph sign resonance spectra of multiple sclerosis lesions. MAGMA 16 (2003) 10-16
111. Whittall K.P., MacKay A.L., Li D.K., et al. Normal-appearing white matter in multiple sclerosis has heterogeneous, diffusely prolonged T(2). Magn Reson Med 47 (2002) 403-408
112. Evangelou N., Esiri M.M., Smith S., et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 47 (2000) 391-395
113. Walters R.J., Fox N.C., Crum W.R., et al. Haemodialysis and cerebral oedema. Nephron 87 (2001) 143-147
114. Mellanby A.R., and Reveley M.A. Effects of acute dehydration on computerized tomographic assessment of cerebral density and ventricular volume. Lancet 2 (1982) 874
115. Rao A.B., Richert N., Howard T., et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 59 (2002) 688-694
116. Zivadinov R., Rudick R.A., De Masi R., et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57 (2001) 1239-1247
117. De Stefano N., Bartolozzi M.L., Nacmias B., et al. Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch Neurol 61 (2004) 536-540
118. Enzinger C., Ropele S., Smith S., et al. Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4. Ann Neurol 55 (2004) 563-569
119. Enzinger C., Fazekas F., Matthews P.M., et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 64 (2005) 1704-1711
120. Kidd D., Barkhof F., McConnell R., et al. Cortical lesions in multiple sclerosis. Brain 122 Pt 1 (1999) 17-26
121. Geurts J.J., Pouwels P.J., Uitdehaag B.M., et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 236 (2005) 254-260
122. Kangarlu A., Bourekas E.C., Ray-Chaudhury A., et al. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol 28 (2007) 262-266
123. Miller D.H., Barkhof F., Frank J.A., et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125 (2002) 1676-1695
124. Battaglini M., Smith S.M., Brogi S., et al. Enhanced brain extraction improves the accuracy of brain atrophy estimation. Neuroimage 40 (2008) 583-589
125. Jasperse B., Valsasina P., Neacsu V., et al. Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. J Magn Reson Imaging 26 (2007) 881-885
126. Bookstein F.L. "Voxel-based morphometry" should not be used with imperfectly registered images. Neuroimage 14 (2001) 1454-1462